ID   Tong/HCC
AC   CVCL_V640
SY   Tong; TONG; TONG/PHC; TONG PHC
DR   cancercelllines; CVCL_V640
DR   GEO; GSM2551595
DR   LIMORE; Tong
DR   Wikidata; Q54972784
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   PubMed=2445644;
RX   PubMed=3023526;
RX   PubMed=8050184;
RX   PubMed=8224613;
RX   PubMed=31378681;
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Population: Caucasian; Italian.
CC   Doubling time: ~50 hours (PubMed=2445644); 26.71 hours (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; c.5125-1G>T; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Leu148Ter (c.443T>A); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=31378681).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): PubMed=31378681
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 14
ST   D16S539: 9
ST   D5S818: 12
ST   D7S820: 8,12
ST   TH01: 8,10
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 17
//
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
//
RX   PubMed=2445644; DOI=10.1002/hep.1840070619;
RA   Stevenson D., Lin J.-H., Tong M.J., Marshall G.J.;
RT   "Characteristics of a cell line (Tong/HCC) established from a human
RT   hepatocellular carcinoma.";
RL   Hepatology 7:1291-1295(1987).
//
RX   PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315;
RA   Aspinall S., Alexander J.J., Bos P.;
RT   "Comparative expression of hepatitis B virus antigens in several cell
RT   model systems.";
RL   J. Gen. Virol. 67:2315-2323(1986).
//
RX   PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x;
RA   Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.;
RT   "HLA expression in hepatocellular carcinoma cell lines.";
RL   Clin. Exp. Immunol. 97:328-333(1994).
//
RX   PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613;
RA   Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E.,
RA   Ponchel F., Yakicier C., Ji J.-W., Ozturk M.;
RT   "Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell
RT   lines.";
RL   FASEB J. 7:1407-1413(1993).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//